• BYLSH

Exagen and Ohio State Partner in Fibromyalgia Blood Test

What would be of more value than gold to someone with Fibromyalgia? A blood test to prove that you live with the disease. It has been decades in the making! While there is the FM test that has been touted on the radio, how legitimate is it? Well folks, it looks like we have a WINNER!! That’s right! Our prayers have finally been answered! Ohio State University and Exagen have teamed up and identified Fibromyalgia markers in a blood test that they have developed. Read the below press releases straight from the Exagen and Ohio State websites.


SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced it has entered into an exclusive worldwide license agreement with the Ohio State Innovation Foundation for the commercial diagnostic development and marketing rights for a novel blood test using vibrational spectroscopy and metabolomic analysis to differentiate patients with fibromyalgia from rheumatoid arthritis, osteo arthritis, chronic lower back pain and systemic lupus erythematosus.


Fibromyalgia is the most common cause of chronic widespread musculoskeletal pain in the US and approximately 90 percent of fibromyalgia sufferers are female. In the US, there may be as many as 12 million undiagnosed patients with fibromyalgia. In a study that was authored by researchers from The Ohio State University and recently published in The Journal of Biological Chemistry, scientists were able to distinguish clear metabolomic patterns that set fibromyalgia blood samples apart from those of other rheumatic diseases.


“Approximately thirty percent of fibromyalgia patients may test positive for anti-nuclear antibodies raising autoimmune disease concerns and resulting in potentially inappropriate referrals to rheumatologists,” said Ron Rocca, Exagen President and Chief Executive Officer. “In addition, patients with fibromyalgia and autoimmune diseases such as lupus and rheumatoid arthritis may have similar symptoms especially in early stage disease, making differential diagnosis difficult. A rule-in test for fibromyalgia would be a significant advancement in the earlier diagnosis and appropriate treatment of these patients.”


The licensed technology is based on the research of Kevin Hackshaw, Luis Rodriguez-Saona and Tony Buffington at The Ohio State University. “Fibromyalgia is often difficult to diagnose,” says Scott Osborne, vice president of economic and corporate engagement at Ohio State. “This research providing evidence that fibromyalgia can be detected in blood samples exemplifies Ohio State’s mission to improve lives by finding solutions to complex problems.”

This article was taken directly from the Exagen website. Read the rest of the press release from Exagen here.




Researchers at The Ohio State University have discovered a new, reliable way to detect fibromyalgia in blood samples, leading the way to quickly identifying a disease that's often misdiagnosed.


About 2 percent of the U.S. population has fibromyalgia, which can cause chronic pain, fatigue, depression, sleep problems and difficulty concentrating. Those who've been diagnosed waited an average of five years between the onset of symptoms and their diagnosis – a long time to be left wondering what's wrong and whether their symptoms are real.


Now, Ohio State experts in medicine and food science have identified biomarkers of fibromyalgia to differentiate it from other, related diseases, such as rheumatoid arthritis or systemic lupus erythematosus, making diagnosis much quicker.


Doctors currently diagnose fibromyalgia based on patient-reported symptoms and a physical evaluation of their pain – there's no clear-cut, easy-to-use tool to provide a quick diagnosis, says researcher Kevin Hackshaw, a rheumatologist at The Ohio State University Wexner Medical Center.


"Here, we found clear, reproducible metabolic patterns in the blood of dozens of patients with fibromyalgia," he says. "This brings us much closer to a blood test than we have ever been."

Hackshaw notes that identification of fibromyalgia biomarkers – a sort of "metabolic fingerprint" – could not only provide reliable diagnoses, but could also lead to targeted fibromyalgia treatments.


This article was taken directly from the Ohio State website. Read the rest of the article from Ohio State here.

45 views0 comments